Skip to main content
SpringerLink
Log in

Depression and Parkinson’s Disease: Current Knowledge

  • Movement Disorders (SA Factor, Section Editor)
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Depressive disturbances are common in patients with Parkinson’s disease (PD) and influence many other clinical aspects of the disease. In addition to causing inherent emotional distress, depressive disorders negatively impact quality of life, motor and cognitive deficits, functional disability, and other psychiatric comorbidities in patients with PD. Knowledge of the pathophysiology of PD depression remains limited. However, clinical studies demonstrate the efficacy of medications and psychotherapies for PD depression, underscoring the importance of their timely detection and concerted management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov Disord. 2009;24:2175–86.

    Article  PubMed  Google Scholar 

  2. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20:190–9.

    Article  PubMed  Google Scholar 

  3. Starkstein SE, Mayberg HS, Leiguarda R, et al. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1992;55:377–82.

    Article  PubMed  CAS  Google Scholar 

  4. Müller B, Assmus J, Herlofson K, Larsen JP, Tysnes OB. Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson's disease. Parkinsonism Relat Disord. 2013. doi:10.1016/j.parkreldis.2013.07.010.

  5. Hughes TA, Ross HF, Mindham RH, Spokes EG. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand. 2004;110:118–23.

    Article  PubMed  CAS  Google Scholar 

  6. Ravina B, Camicioli R, Como PG, et al. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007;69:342–7.

    Article  PubMed  CAS  Google Scholar 

  7. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord. 2002;8:193–7.

    Article  PubMed  CAS  Google Scholar 

  8. Weintraub D, Moberg PJ, Duda JE, et al. Recognition and treatment of depression in Parkinson's disease. J Geriatr Psychiatry Neurol. 2003;16:178–83.

    Article  PubMed  Google Scholar 

  9. van der Hoek TC, Bus BA, Matui P, et al. Prevalence of depression in Parkinson's disease: effects of disease stage, motor subtype and gender. J Neurol Sci. 2011;310:220–4.

    Article  PubMed  Google Scholar 

  10. Dobkin RD, Rubino JT, Friedman J, et al. Barriers to mental health care utilization in Parkinson's disease. J Geriatr Psychiatry Neurol. 2013;26:105–16.

    Article  PubMed  Google Scholar 

  11. Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord. 2008;23:183–9. quiz 313.

    Article  PubMed  Google Scholar 

  12. Slaughter JR, Slaughter KA, Nichols D, et al. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2001;13:187–96.

    Article  PubMed  CAS  Google Scholar 

  13. • Williams JR, Hirsch ES, Anderson K, Bush AL, Goldstein SR, Grill S, et al. A comparison of nine scales to detect depression in Parkinson disease: which scale to use? Neurology. 2012;78:998–1006. This study analyzed and summarizes the psychometric properties of commonly used depression rating scales in PD patients.

    Article  PubMed  CAS  Google Scholar 

  14. GPDS Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord. 2002;17:60–7.

    Article  Google Scholar 

  15. Rojo A, Aguilar M, Garolera MT, et al. Depression in Parkinson's disease: clinical correlates and outcome. Parkinsonism Relat Disord. 2003;10:23–8.

    Article  PubMed  CAS  Google Scholar 

  16. Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand. 2006;113:211–20.

    Article  PubMed  CAS  Google Scholar 

  17. • Aarsland D, Pahlhagen S, Ballard CG, et al. Depression in Parkinson disease - epidemiology, mechanisms, and management. Nat Rev Neurol. 2012;8:35–47. This is a detailed review of the pathophysiological mechanisms identified in PD.

    Article  CAS  Google Scholar 

  18. Brown RG, MacCarthy B, Gotham AM, et al. Depression and disability in Parkinson's disease: a follow-up of 132 cases. Psychol Med. 1988;18:49–55.

    Article  PubMed  CAS  Google Scholar 

  19. Menza M, Dobkin RD, Marin H, et al. The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease. Mov Disord. 2009;24:1325–32.

    Article  PubMed  Google Scholar 

  20. Ravina B, Elm J, Camicioli R, et al. The course of depressive symptoms in early Parkinson's disease. Mov Disord. 2009;24:1306–11.

    Article  PubMed  Google Scholar 

  21. Paumier KL, Siderowf AD, Auinger P, et al. Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease. Mov Disord. 2012;27:880–7.

    Article  PubMed  CAS  Google Scholar 

  22. Menza MA, Robertson-Hoffman DE, Bonapace AS. Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry. 1993;34:465–70.

    Article  PubMed  CAS  Google Scholar 

  23. • Dobkin RD, Menza M, Bienfait KL, et al. Depression in Parkinson's disease: symptom improvement and residual symptoms after acute pharmacologic management. Am J Geriatr Psychiatr. 2011;19:222–9. This was the first major controlled trial of CBT for depression in PD.

    Article  Google Scholar 

  24. Dobkin RD, Menza M, Bienfait KL, et al. The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2010;22:188–95.

    Article  PubMed  Google Scholar 

  25. Alexopoulos GS, Kiosses DN, Heo M, et al. Executive dysfunction and the course of geriatric depression. Biol Psychiatry. 2005;58:204–10.

    Article  PubMed  Google Scholar 

  26. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006;5:235–45.

    Article  PubMed  Google Scholar 

  27. Mayberg HS, Solomon DH. Depression in Parkinson's disease: a biochemical and organic viewpoint. Adv Neurol. 1995;65:49–60.

    PubMed  CAS  Google Scholar 

  28. Ehmann TS, Beninger RJ, Gawel MJ, Riopelle RJ. Depressive symptoms in Parkinson's disease: a comparison with disabled control subjects. J Geriatr Psychiatry Neurol. 1990;3:3–9.

    Article  PubMed  CAS  Google Scholar 

  29. • Rod NH, Bordelon Y, Thompson A, et al. Major life events and development of major depression in Parkinson's disease patients. Eur J Neurol. 2013;20:663–70. This is a reminder that life events, and not just PD, influence the development of depressive disturbances.

    Article  PubMed  CAS  Google Scholar 

  30. Matsui H, Nishinaka K, Oda M, et al. Minor depression and brain perfusion images in Parkinson's disease. Mov Disord. 2006;21:1169–74.

    Article  PubMed  Google Scholar 

  31. Mayberg HS, Starkstein SE, Sadzot B, et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol. 1990;28:57–64.

    Article  PubMed  CAS  Google Scholar 

  32. Weintraub D, Newberg AB, Cary MS, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. J Nucl Med. 2005;46:227–32.

    PubMed  CAS  Google Scholar 

  33. Vriend C, Raijmakers P, Veltman DJ, et al. Depressive symptoms in Parkinson's disease are related to reduced [123I]FP-CIT binding in the caudate nucleus. J Neurol Neurosurg Psychiatry. 2013. doi:10.1136/jnnp-2012-304811.

  34. Kostic VS, Agosta F, Petrovic I, et al. Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology. 2010;75:857–63.

    Article  PubMed  CAS  Google Scholar 

  35. Matsui H, Nishinaka K, Oda M, et al. Depression in Parkinson's disease. Diffusion tensor imaging study. J Neurol. 2007;254:1170–3.

    Article  PubMed  Google Scholar 

  36. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cortical cholinergic denervation is associated with depressive symptoms in Parkinson's disease and parkinsonian dementia. J Neurol Neurosurg Psychiatry. 2007;78:641–3.

    Article  PubMed  CAS  Google Scholar 

  37. • Huot P, Fox SH. The serotonergic system in motor and non-motor manifestations of Parkinson's disease. Exp Brain Res. 2013;230(4):463–76. This is a detailed review of the evidence, or lack of evidence, for serotonin mechanisms in PD depression.

    Google Scholar 

  38. Politis M, Wu K, Loane C, et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology. 2010;75:1920–7.

    Article  PubMed  CAS  Google Scholar 

  39. Grachev ID. Dopamine transporter imaging with [123I]FP-CIT (DaTSCAN) in Parkinson's disease with depressive symptoms: a biological marker for causal relationships? J Neurol Neurosurg Psychiatry. 2013. doi:10.1136/jnnp-2013-305380.

  40. Bronstein J, Carvey P, Chen H, et al. Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007. Environ Health Perspect. 2009;117:117–21.

    PubMed  Google Scholar 

  41. Tan SK, Hartung H, Sharp T, Temel Y. Serotonin-dependent depression in Parkinson's disease: a role for the subthalamic nucleus? Neuropharmacology. 2011;61:387–99.

    Article  PubMed  CAS  Google Scholar 

  42. Bejjani BP, Damier P, Arnulf I, et al. Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med. 1999;340:1476–80.

    Article  PubMed  CAS  Google Scholar 

  43. Blomstedt P, Hariz MI, Lees A, et al. Acute severe depression induced by intraoperative stimulation of the substantia nigra: a case report. Parkinsonism Relat Disord. 2008;14:253–6.

    Article  PubMed  Google Scholar 

  44. • Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67:58–63. This is an example of keen and consistent clinical observations resulting in the description of a relatively common and challenging, but previously unrecognized, clinical syndrome.

    Article  PubMed  Google Scholar 

  45. Arabia G, Grossardt BR, Geda YE, et al. Increased risk of depressive and anxiety disorders in relatives of patients with Parkinson disease. Arch Gen Psychiatry. 2007;64:1385–92.

    Article  PubMed  Google Scholar 

  46. Kasten M, Kertelge L, Bruggemann N, et al. Nonmotor symptoms in genetic Parkinson disease. Arch Neurol. 2010;67:670–6.

    Article  PubMed  Google Scholar 

  47. Belarbi S, Hecham N, Lesage S, et al. LRRK2 G2019S mutation in Parkinson's disease: a neuropsychological and neuropsychiatric study in a large Algerian cohort. Parkinsonism Relat Disord. 2010;16:676–9.

    Article  PubMed  Google Scholar 

  48. Marras C, Schule B, Munhoz RP, et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology. 2011;77:325–33.

    Article  PubMed  CAS  Google Scholar 

  49. Srivastava A, Tang MX, Mejia-Santana H, et al. The relation between depression and parkin genotype: the CORE-PD study. Parkinsonism Relat Disord. 2011;17:740–4.

    Article  PubMed  CAS  Google Scholar 

  50. Mossner R, Henneberg A, Schmitt A, et al. Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. Mol Psychiatry. 2001;6:350–2.

    Article  PubMed  CAS  Google Scholar 

  51. Menza MA, Palermo B, DiPaola R, et al. Depression and anxiety in Parkinson's disease: possible effect of genetic variation in the serotonin transporter. J Geriatr Psychiatry Neurol. 1999;12:49–52.

    Article  PubMed  CAS  Google Scholar 

  52. Burn DJ, Tiangyou W, Allcock LM, et al. Allelic variation of a functional polymorphism in the serotonin transporter gene and depression in Parkinson's disease. Parkinsonism Relat Disord. 2006;12:139–41.

    Article  PubMed  Google Scholar 

  53. Dissanayaka NN, Silburn PA, O'Sullivan JD, Mellick GD. Serotonin and dopamine transporter genes do not influence depression in Parkinson's disease. Mov Disord. 2009;24:111–5.

    Article  PubMed  Google Scholar 

  54. Zhang JL, Yang JF, Chan P. No association between polymorphism of serotonin transporter gene and depression in Parkinson's disease in Chinese. Neurosci Lett. 2009;455:155–8.

    Article  PubMed  CAS  Google Scholar 

  55. Starkstein SE, Merello M, Jorge R, et al. A validation study of depressive syndromes in Parkinson's disease. Mov Disord. 2008;23:538–46.

    Article  PubMed  Google Scholar 

  56. Cheng EM, Tonn S, Swain-Eng R, et al. Quality improvement in neurology: AAN Parkinson disease quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. Neurology. 2010;75:2021–7.

    Article  PubMed  CAS  Google Scholar 

  57. Marsh L, McDonald WM, Cummings J, Ravina B. Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH work group. Mov Disord. 2006;21:148–58.

    Article  PubMed  Google Scholar 

  58. Leentjens AF, Dujardin K, Marsh L, et al. Symptomatology and markers of anxiety disorders in Parkinson's disease: a cross-sectional study. Mov Disord. 2011;26:484–92.

    Article  PubMed  Google Scholar 

  59. Nazem S, Siderowf AD, Duda JE, et al. Suicidal and death ideation in Parkinson's disease. Mov Disord. 2008;23:1573–9.

    Article  PubMed  Google Scholar 

  60. Weintraub D, Duda JE, Carlson K, Luo P, Sagher O, Stern M, et al. Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: results from a randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2013;84(10):1113–8.

    Google Scholar 

  61. Engmann B. Bipolar affective disorder and Parkinson's disease. Case Rep Med. 2011;2011:154165.

    PubMed  Google Scholar 

  62. Racette BA, Hartlein JM, Hershey T, et al. Clinical features and comorbidity of mood fluctuations in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2002;14:438–42.

    Article  PubMed  Google Scholar 

  63. Leentjens AF, Dujardin K, Marsh L, et al. Anxiety and motor fluctuations in Parkinson's disease: a cross-sectional observational study. Parkinsonism Relat Disord. 2012;18:1084–8.

    Article  PubMed  CAS  Google Scholar 

  64. Riedel O, Klotsche J, Spottke A, et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J Neurol. 2010;257:1073–82.

    Article  PubMed  Google Scholar 

  65. Starkstein SE, Bolduc PL, Mayberg HS, et al. Cognitive impairments and depression in Parkinson's disease: a follow up study. J Neurol Neurosurg Psychiatry. 1990;53:597–602.

    Article  PubMed  CAS  Google Scholar 

  66. Leentjens AF, Lousberg R, Verhey FR. Markers for depression in Parkinson's disease. Acta Psychiatr Scand. 2002;106:196–201.

    Article  PubMed  CAS  Google Scholar 

  67. Marsh L, Williams JR, Rocco M, et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology. 2004;63:293–300.

    Article  PubMed  CAS  Google Scholar 

  68. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson's disease. J Nerv Ment Dis. 1990;178:27–31.

    Article  PubMed  CAS  Google Scholar 

  69. Starkstein SE, Petracca G, Chemerinski E, et al. Depression in classic versus akinetic-rigid Parkinson's disease. Mov Disord. 1998;13:29–33.

    Article  PubMed  CAS  Google Scholar 

  70. Frisina PG, Borod JC, Foldi NS, Tenenbaum HR. Depression in Parkinson's disease: health risks, etiology, and treatment options. Neuropsychiatr Dis Treat. 2008;4:81–91.

    PubMed  Google Scholar 

  71. Weintraub D, Burn DJ. Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord. 2011;26:1022–31.

    Article  PubMed  Google Scholar 

  72. Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008;23:850–7.

    Article  PubMed  Google Scholar 

  73. Dobkin RD, Menza M, Allen LA, et al. Telephone-based cognitive-behavioral therapy for depression in Parkinson disease. J Geriatr Psychiatry Neurol. 2011;24:206–14.

    Article  PubMed  Google Scholar 

  74. Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012;78:1229–36.

    Article  PubMed  CAS  Google Scholar 

  75. Veazey C, Cook KF, Stanley M, et al. Telephone-administered cognitive behavioral therapy: a case study of anxiety and depression in Parkinson's disease. J Clin Psychol Med Settings. 2009;16:243–53.

    Article  PubMed  Google Scholar 

  76. Dobkin RD, Menza M, Allen LA, et al. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. Am J Psychiatry. 2011;168:1066–74.

    Article  PubMed  Google Scholar 

  77. • Armento M, Stanley M, Marsh L, et al. Cognitive behavioral therapy (CBT) for depression and anxiety in Parkinson’s disease: a clinical review. J Park Dis. 2012;2:135–51. This is a systematic review of CBT studies in PD.

    Google Scholar 

  78. Gaynes BN, Rush AJ, Trivedi MH, et al. The STAR*D study: treating depression in the real world. Cleve Clin J Med. 2008;75:57–66.

    Article  PubMed  Google Scholar 

  79. Price A, Rayner L, Okon-Rocha E, et al. Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry. 2011;82:914–23.

    Article  PubMed  Google Scholar 

  80. • van der Marck MA, Bloem BR, Borm GF, et al. Effectiveness of multidisciplinary care for Parkinson's disease: a randomized, controlled trial. Mov Disord. 2013;28:605–11. The results of this study underscore the importance of collaborative multidisciplinary care.

    Article  PubMed  Google Scholar 

  81. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:573–80.

    Article  PubMed  CAS  Google Scholar 

  82. Andersen J, Aabro E, Gulmann N, et al. Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA. Acta Neurol Scand. 1980;62:210–9.

    Article  PubMed  CAS  Google Scholar 

  83. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009;72:886–92.

    Article  PubMed  CAS  Google Scholar 

  84. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2011;26 Suppl 3:S42–80.

    Article  PubMed  Google Scholar 

  85. Skapinakis P, Bakola E, Salanti G, et al. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol. 2010;10:49.

    Article  PubMed  Google Scholar 

  86. Arbouw ME, Movig KL, Neef C, et al. Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients. Eur J Clin Pharmacol. 2007;63(2):181–97.

    Article  PubMed  CAS  Google Scholar 

  87. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology. 1997;48:1070–7.

    Article  PubMed  CAS  Google Scholar 

  88. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361:1268–78.

    Article  PubMed  CAS  Google Scholar 

  89. Imamura K, Okayasu N, Nagatsu T. The relationship between depression and regional cerebral blood flow in Parkinson's disease and the effect of selegiline treatment. Acta Neurol Scand. 2011;124:28–39.

    Article  PubMed  CAS  Google Scholar 

  90. Leentjens AF. The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review. Drugs. 2011;71:273–86.

    Article  PubMed  CAS  Google Scholar 

  91. Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253:601–7.

    Article  PubMed  CAS  Google Scholar 

  92. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol. 2003;10:399–406.

    Article  PubMed  CAS  Google Scholar 

  93. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68:1108–15.

    Article  PubMed  CAS  Google Scholar 

  94. Navan P, Findley LJ, Jeffs JA, et al. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor. Mov Disord. 2003;18:1324–31.

    Article  PubMed  Google Scholar 

  95. da Silva TM, Munhoz RP, Alvarez C, et al. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord. 2008;111:351–9.

    Article  PubMed  Google Scholar 

  96. Pal E, Nagy F, Aschermann Z, et al. The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: a randomized, double-blind, placebo-controlled study. Mov Disord. 2010;25:2311–7.

    Article  PubMed  Google Scholar 

  97. Boggio PS, Fregni F, Bermpohl F, et al. Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression. Mov Disord. 2005;20:1178–84.

    Article  PubMed  Google Scholar 

  98. Fregni F, Santos CM, Myczkowski ML, et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004;75:1171–4.

    Article  PubMed  CAS  Google Scholar 

  99. Faber R, Trimble MR. Electroconvulsive therapy in Parkinson's disease and other movement disorders. Mov Disord. 1991;6:293–303.

    Article  PubMed  CAS  Google Scholar 

  100. Holtzheimer PE, Mayberg HS. Deep brain stimulation for psychiatric disorders. Annu Rev Neurosci. 2011;34:289–307.

    Article  PubMed  CAS  Google Scholar 

  101. Sproesser E, Viana MA, Quagliato EM, de Souza EA. The effect of psychotherapy in patients with PD: a controlled study. Parkinsonism Relat Disord. 2010;16:298–300.

    Article  PubMed  Google Scholar 

  102. Serfaty MA, Haworth D, Blanchard M, et al. Clinical effectiveness of individual cognitive behavioral therapy for depressed older people in primary care: a randomized controlled trial. Arch Gen Psychiatry. 2009;66:1332–40.

    Article  PubMed  Google Scholar 

  103. Mohr DC, Likosky W, Bertagnolli A, et al. Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis. J Consult Clin Psychol. 2000;68:356–61.

    Article  PubMed  CAS  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Laura Marsh has been a consultant for Roche Pharmaceuticals for the development of clinical trial designs to test interventions for apathy in Parkinson's disease. She is employed by the Michael E. DeBakey Veterans Affairs Medical Center. She is a site investigator for the Dystonia Coalition U54 NS065701.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Author information

Authors and Affiliations

  1. Baylor College of Medicine, Departments of Psychiatry and Neurology, Michael E. DeBakey Veterans Affairs Medical Center, Mental Health Care Line (116), 2002 Holcombe Boulevard, Houston, TX, 77030, USA

    Laura Marsh

Authors
  1. Laura Marsh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laura Marsh.

Additional information

This article is part of the Topical Collection on Movement Disorders

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marsh, L. Depression and Parkinson’s Disease: Current Knowledge. Curr Neurol Neurosci Rep 13, 409 (2013). https://doi.org/10.1007/s11910-013-0409-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11910-013-0409-5

Keywords

Search

Navigation